Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated with Prolonged Survival in Patients with Pancreatic Cancer?

Jin He, Alex B. Blair, Vincent P. Groot, Ammar A. Javed, Richard A. Burkhart, Georgios Gemenetzis, Ralph H. Hruban, Kevin M. Waters, Justin Poling, Lei Zheng, Daniel Laheru, Joseph M. Herman, Martin A. Makary, Matthew J. Weiss, John L. Cameron, Christopher L. Wolfgang

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To describe the survival outcome of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic complete response (pCR) following neoadjuvant chemoradiation. Background: Patients with BR/LA-PDAC are often treated with neoadjuvant chemoradiation in an attempt to downstage the tumor. Uncommonly, a pCR may result. Methods: A retrospective review of a prospectively maintained database was performed at a single institution. pCR was defined as no viable tumor identified in the pancreas or lymph nodes by pathology. A near complete response (nCR) was defined as a primary tumor less than 1 cm, without nodal metastasis. Overall survival (OS) and disease-free survival (DFS) were reported. Results: One hundred eighty-six patients with BR/LA-PDAC underwent neoadjuvant chemoradiation and subsequent pancreatectomy. Nineteen patients (10%) had a pCR, 29 (16%) had an nCR, and the remaining 138 (74%) had a limited response. Median DFS was 26 months in patients with pCR, which was superior to nCR (12 months, P = 0.019) and limited response (12 months, P < 0.001). The median OS of nCR (27 months, P = 0.003) or limited response (26 months, P = 0.001) was less than that of pCR (more than 60 months). In multivariable analyses pCR was an independent prognostic factor for DFS (HR = 0.45; 0.22-0.93, P = 0.030) and OS (HR=0.41; 0.17-0.97, P = 0.044). Neoadjuvant FOLFIRINOX (HR=0.47; 0.26-0.87, P = 0.015) and negative lymph node status (HR=0.57; 0.36-0.90, P = 0.018) were also associated with improved survival. Conclusions: Patients with BR/LA-PDAC who had a pCR after neoadjuvant chemoradiation had a significantly prolonged survival compared with those who had nCR or a limited response.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalAnnals of surgery
Volume268
Issue number1
DOIs
StatePublished - Jul 1 2018

Keywords

  • borderline resectable
  • locally advanced
  • neoadjuvant therapy
  • pancreatectomy
  • pancreatic ductal adenocarcinoma
  • pathologic complete response
  • survival

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated with Prolonged Survival in Patients with Pancreatic Cancer?'. Together they form a unique fingerprint.

Cite this